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Rho GTPases (20 human members) comprise a major branch
of the Ras superfamily of small GTPases, and aberrant Rho
GTPase function has been implicated in oncogenesis and other
human diseases. Althoughmany of our current concepts of Rho
GTPases are based on the three classical members (RhoA, Rac1,
and Cdc42), recent studies have revealed the diversity of biolog-
ical functionsmediatedbyother familymembers.Akey basis for
the functional diversity of RhoGTPases is their associationwith
distinct subcellular compartments, which is dictated in part by
three posttranslational modifications signaled by their carbox-
yl-terminalCAAX (whereC represents cysteine,A is an aliphatic
amino acid, and X is a terminal amino acid) tetrapeptidemotifs.
CAAXmotifs are substrates for the prenyltransferase-catalyzed
addition of either farnesyl or geranylgeranyl isoprenoid lipids,
Rce1-catalyzed endoproteolytic cleavage of the AAX amino
acids, and Icmt-catalyzed carboxylmethylationof the isoprenyl-
cysteine. We utilized pharmacologic, biochemical, and genetic
approaches to determine the sequence requirements and roles
of CAAX signal modifications in dictating the subcellular loca-
tions and functions of the Rho GTPase family. Although the
classical Rho GTPases are modified by geranylgeranylation, we
found that a majority of the other Rho GTPases are substrates
for farnesyltransferase. We found that the membrane associa-
tion and/or function of Rho GTPases are differentially depend-
ent on Rce1- and Icmt-mediatedmodifications. Our results fur-
ther delineate the sequence requirements for prenyltransferase
specificity and functional roles for protein prenylation in Rho
GTPase function. We conclude that a majority of Rho GTPases
are targets for pharmacologic inhibitors of farnesyltransferase,
Rce1, and Icmt.
Rho proteins are members of the Ras superfamily of small
GTPases and function as GDP/GTP-regulated switches (1, 2).
Much of our current understanding of the biochemistry and
biology of the Rho family has come from the extensive evalua-
tion of three classical members, RhoA, Rac1, and Cdc42 (3).
Similar to Ras, Rho GDP/GTP cycling is regulated by guanine
nucleotide exchange factors that promote the formation of the
active GTP-bound form (4) and GTPase-activating proteins
that catalyze the intrinsic GTPase activity and promote the for-
mation of inactive GDP-bound Rho (5). Active, GTP-bound
Rho GTPases bind preferentially to downstream effectors,
stimulating diverse cytoplasmic signaling cascades that control
actin reorganization and regulate cell shape, polarity, motility,
adhesion, and membrane trafficking (6). As such, it is thought
that activated Rho proteins contribute to cancer progression by
influencing the ability of cells tomigrate and thus to invade and
metastasize. In addition to these alterations in cellular function,
aberrant activation of Rho proteins has also been shown to con-
tribute to other cancer phenotypes by promoting cell growth,
proliferation, survival, and angiogenesis (7). Therefore, defin-
ing pharmacologic approaches for inhibition of Rho GTPase
function represents an important direction for target-based
anti-cancer drug discovery.
Similar toRas, themajority of Rho familyGTPases are known
or anticipated to undergo a series of posttranslational modifi-
cations that promote proper subcellular localization to the
plasma membrane and/or endomembranes, which is required
for biological activity. This series ofmodifications is initiated by
the recognition of a carboxyl-terminal CAAX tetrapeptide
motif (whereC represents cysteine,A is an aliphatic amino acid,
and X is any amino acid), which is found on 16 of 20 Rho
GTPases (Table 1; canonical CAAX motifs are not present in
the Wrch-1, Chp/Wrch-2, RhoBTB1, or RhoBTB2). The first
step, mediated by farnesyltransferase (FTase)2 and/or gera-
nylgeranyltransferase type I (GGTase-I), results in the covalent
addition of a farnesyl or geranylgeranyl isoprenoid lipid, respec-
tively, to the cysteine residue of the CAAX sequence. Next, the
-AAXpeptide is cleaved from the carboxyl terminus by theRce1
(Ras-converting enzyme 1) endoprotease. Finally, isoprenylcys-
teine-O-carboxyl methyltransferase (Icmt) catalyzes the addi-
tion of a methyl group to the prenylated cysteine residue (8).
Together, these modifications increase protein hydrophobicity
and facilitate membrane association. Where studied, mutation
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of the cysteine residue of the CAAX motif, which prevents all
three modifications, renders Rho GTPases inactive due to mis-
localization to the cytosol (9). Thus, pharmacological inhibitors
of protein prenylation are anticipated to be effective inhibitors
of RhoGTPase activity. Recent observations upon genetic abla-
tion of GGTase-I activity support this possibility. Transient
genetic depletion of GGTase-I caused mouse embryonic fibro-
blasts to undergo growth arrest, cell rounding, impaired cell
migration, and reduced actin polymerization, and these pheno-
typic alterationswere partially rescued byGGTase-I-independ-
ent, farnesylated variants of RhoA and Cdc42 (10). These phe-
notypic consequences are consistent with loss of Rho GTPase
function but additionally suggest that multiple GGTase-I sub-
strates are important for regulation of cell morphology and
actin organization. Similarly, loss of GGTase-I activity was
lethal in the budding yeast Saccharomyces cerevisiae, and the
combined expression of GGTase-I-independent, farnesylated
variants of RhoA and Cdc42 suppressed this lethality (11).
Although the CAAX-signaled posttranslational modifica-
tions are necessary for Ras and RhoGTPase function andmem-
brane association, these three modifications alone are not suf-
ficient to promote full membrane association or to target the
proteins to the specific cellular subdomains required for proper
GTPase function (12). Instead, at least two distinct sequence
elements positioned immediately upstream of the CAAXmotif
serve as additional signals that are required to promote efficient
membrane association and biological function. One element is
composed of clusters of polybasic amino acid residues, as seen
in K-Ras4B, that provide a positive charge that facilitates asso-
ciation with acidic membrane-associated lipids. The second
sequence element present upstream of CAAX in some Rho
GTPases is one or two cysteine residues that undergo post-
translationalmodification by the fatty acid palmitate. Palmitoy-
lated cysteines comprise the additional targeting signal for
H-Ras and N-Ras proteins as well as for some Rho family
GTPases (RhoB and TC10). Mutant Ras proteins that undergo
the CAAX-signaled modifications but lack either the polybasic
residues or palmitoylated cysteine(s) are mislocalized and are
significantly compromised in their biological activities. Finally,
additional sequences flanking these elements form a largely
uncharacterized third signal that also contributes to dictating
the precise subcellular localization of Ras and Rho GTPases
(13–15). These locations can vary significantly; whereas some
Rho GTPases are found predominantly at the plasma mem-
brane (e.g. Rac1), some are associated mainly with endomem-
branes (e.g. RhoH), and still others are associated with endo-
somes (e.g. RhoD) (Table 1).
Because of the importance of CAAX-signaled modifications
for small GTPase localization and function, farnesyltransferase
inhibitors (FTIs) were developed initially as anti-Ras therapies
for cancer treatment. Unfortunately, K-Ras andN-Ras (the two
Ras isoforms most commonly mutated in human cancers)
undergo alternative prenylation byGGTase-I when in the pres-
ence of FTIs and therefore escape FTI-mediated inhibition of
membrane association (16, 17). Nevertheless, FTIs have exhib-
ited anti-tumor activity in preclinical and clinical trial analyses,
presumably due to the inhibition of function of other FTase
substrates (8). In light of the role of aberrant Rho GTPase func-
tion in oncogenesis, Rho family GTPases (e.g. RhoB) are logical
candidates for key targets of FTIs (18). Although GGTase-I
modifies the classical Rho GTPases, the nature of the CAAX
sequences of other members suggests that they may be FTase
substrates.
The observation that K-Ras and N-Ras undergo alternative
prenylation in response to FTI treatment has also stimulated
interest in the development of inhibitors that block other
enzymes that facilitate Ras membrane association. First,
GGTase-I inhibitors (GGTIs) were developed to block the
function of the alternatively prenylated Ras proteins (19). Fur-
thermore, with increasing evidence for the involvement of nor-
mally geranylgeranylated proteins in cancer (e.g. Ral and Rho
GTPases) (7, 20), there is now additional interest in the devel-
opment of GGTIs to target these GGTase-I substrates for can-
cer treatment. Second, efforts to develop inhibitors of Rce1 and
Icmt as novel anti-cancer agents have recently intensified (9).
However, there is concern regarding their effectiveness, since
Ras proteins that fail to undergo these two modifications do
retain partial localization and function (21, 22). Additionally,
since many FTase and GGTase-I substrates are also substrates
for these two enzymes, there is also concern that such inhibitors
will affect a broad array of cellular proteins and cause signifi-
cant cell toxicity in normal cells. Support for this latter concern
is provided by the observed embryonic lethality in mice defi-
cient in either Rce1 or Icmt. Whether similar toxicity would be
seen in adult animals is an important area of investigation.
In light of the essential function of Rho family GTPases in
normal cell physiology and their aberrant activation in onco-
genesis (7, 20), establishing the sensitivity of Rho GTPases to
FTI and GGTI inhibitors and the contribution of Rce1- and
Icmt-catalyzed modifications to their cellular functions will be
critical to the successful development of inhibitors of CAAX-
signaled modifications. Therefore, we have utilized pharmaco-
logic and genetic approaches to establish the importance of
CAAX-signaledmodifications for the functions of the less stud-
ied Rho GTPases. We found that, in contrast to the common
perception based on the study of the classical Rho GTPases,
farnesylation is a lipid modification that is equally important as
geranylgeranylation for Rho GTPase function. Furthermore,
we conclude that the rules governing palmitoylation of cys-
teine-containing signal sequences and even CAAX tetrapeptide
prenyltransferase specificity derived from structural studies are
imprecise and that experimental analyses are still required to
establish the lipid modification status of a particular CAAX-
terminating protein. Finally, our observations that RhoGTPase
subcellular localization and/or function depend onRce1 and/or
Icmt enzymatic activity support the value of developing inhib-
itors of these two enzymes as therapeutic strategies to block
Rho GTPase function.
EXPERIMENTAL PROCEDURES
Expression Constructs and Cell Culture Lipid Inhibitor
Analyses—cDNAs for human Ras and Rho GTPases (H-Ras,
K-Ras, RhoA, Rnd1, and Rnd2 and Rnd3, RhoD, RhoH, TC10,
TCL, and Rif) and rat RhoB were cloned into pEGFP mamma-
lian expression vectors (Clontech) as previously described (23,
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24) or constructed for this study. All constructs were sequence-
verified, and cloning details are available upon request.
HEK 293T cells were maintained in Dulbecco’s modifiedmini-
mum essential medium supplemented with 10% fetal calf serum
(Sigma), 100 units/ml penicillin, and 100 g/ml streptomycin.
NIH 3T3 cells weremaintained inDulbecco’smodifiedminimum
essentialmedium supplementedwith 10% calf serum (Sigma) and
100 units/ml penicillin and 100 g/ml streptomycin (“complete
growth medium”). Spontaneously immortalized mouse embry-
onic fibroblasts (MEFs) were originally prepared from Icmt/
and Rce1/ mouse embryos, along with control fibroblasts
(Icmt/ and Rce1/) from littermate embryos (25) and were
kindly provided by Stephen G. Young (UCLA, Los Angeles, CA).
MEF cultures were maintained in Dulbecco’s modifiedminimum
essential medium supplemented with 15% calf serum (Colorado
Serum, Denver, CO), nonessential amino acids, and L-glutamine.
The highly selective inhibitors of FTase (FTI-2153) and of
GGTase-I (GGTI-2417) were provided by Saı̈d Sebti (Moffitt
Cancer Center) and Andrew Hamilton (Yale) and were dis-
solved in DMSO (26, 27). The palmitate analog 2-bromopalmi-
tate (2-BP), an inhibitor widely used to evaluate the role of pro-
tein palmitoylation in protein targeting (28–30), was
purchased from Sigma and dissolved in ethanol. Control cul-
tures were treated with the equivalent final concentration of
ethanol or DMSO (designated vehicle). In the inhibitor assays,
cells were transfected as described below, washed, and incu-
bated for 20 h with growth medium supplemented with 10 M
FTI-2153, 10 M GGTI-2417, or 100 M 2-BP.
Transfection, Immunofluorescence, andMicroscopy—For live
cell microscopy, cells were plated, transfected, and imaged in a
35-mm culture dish that incorporated a number 1.5 glass cov-
erslip-sealed 15-mm cut-out on the bottom (MatTek, Ashland,
MA). Uncoated dishes were used for NIH 3T3 cells, and poly-
D-lysine-coated dishes were used for all experiments using
MEFs. DNA transfections were performed with Lipofectamine
Plus reagent according to the manufacturer’s instructions
(Invitrogen). Three h after transfection, cells were washed,
grown in phenol red-freeDulbecco’smodifiedminimumessen-
tial medium/F-12 supplemented with 10% calf serum, and
treated with inhibitors where indicated.
For immunofluorescence, cells transiently transfected with
plasmid DNAs encoding GFP fusion constructs of small
GTPases were fixed 24 h after transfection with 4% paraform-
aldehyde, permeabilized with Triton X-100, stained with Alexa
594-phalloidin (Molecular Probes, Inc., Eugene, OR), and
mounted with FluorSave (Calbiochem).
For both live cell imaging and immunofluorescence studies,
cells were examined with an inverted laser-scanning confocal
microscope (Zeiss 510 LSM) using an oil immersion 63
numerical aperture 1.4 objective. Images were captured by
scanning with the 488 nm spectral line of an argon-ion laser
using the LP 505 emission filter (for live cell imaging; GFP) or
sequential scanning with the 488 nm argon laser and the 543
nm HeNe1 laser and the BP 505–530 (for GFP) or LP 585 (for
Alexa 594) emission filters. 0.3-m confocal z-sections that
show both nuclear and membrane/cytosolic localization of
GFP fusion proteins were obtained and analyzed. Brightness
and contrast of JPEG images were adjusted using Adobe Pho-
toshop CS2 software.
Transformation Assays—For soft agar colony formation
analyses of anchorage-independent growth, NIH 3T3 cells sta-
bly expressing activated Rac or RacC178Smutants were seeded
at a density of 105 cells/60-mm dish in a solution of complete
growth medium containing 0.4% bacto-agar over a layer of
complete growth medium containing 0.6% bacto-agar. Colo-
nies were allowed to form for 2 weeks, after which viable colo-
nies were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide tetrazolium salt. Plates were scanned,
and the number of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide-positive colonies was quantified using
ImageJ software. Results for transformation assays are repre-
sentative of at least three experiments from independently gen-
erated sets of stable cell lines.
1-Biotinamido-4-(4-(maleimidomethyl Cyclohexanecarbox-
amido) Butane (Biotin-BMCC) Labeling—Analyses of protein
palmitoylation were done as described in Refs. 31 and 32).
Briefly, 293T cells were transfected with 7 g of the indicated
pEGFP construct using a calcium phosphate transfection tech-
nique. Forty-eight h after transfection, cells were lysed and
incubated with 5 g of anti-GFP monoclonal antibody (JL-8;
Clontech) at 4 °C for 1 h, at which point 20 g of protein G
(Invitrogen) was added to the lysates and incubated at 4 °C for
1 h. Bound protein was washed and incubated with lysis buffer
containing 50 mM N-ethylmaleimide (Sigma) for 48 h at 4 °C.
Bound protein was then washed and treated with 1 M hydrox-
ylamine, pH 7.4, to cleave thioester bonds for 1 h at 25 °C,washed
again, and treated with biotin-BMCC (Pierce), which recognizes
free sulfhydryl groups, for 2 h at 25 °C. Bound protein was washed
again, resuspended in 50 l of 2 sample loading buffer, resolved
by 12% SDS-PAGE, and transferred to polyvinylidene difluoride
membrane. Labeled protein was detected by incubation with
streptavidin-horseradish peroxidase (Pierce), and the membrane
was washed and exposed to x-ray film. Twenty g of lysate was
resolved by SDS-PAGE, transferred, incubatedwith anti-GFP pri-
mary antibody and anti-mouse IgG-horseradish peroxidase sec-
ondary antibody, and exposed to x-ray film to verify the presence
of each GFP-tagged protein.
In Vitro Prenylation Analyses—Full-length human Rnd,
RhoB, and TC10 proteins were expressed as fusion proteins
containing six histidine residues at the amino terminus. The
cDNA coding regions were amplified from appropriate cell
lines by PCR and subcloned into the pQE bacterial expression
vector (Qiagen). The identity of all plasmids was confirmed by
restriction mapping and DNA sequencing of the PCR-ampli-
fied fragments. Six-histidine-tagged Rnd1, Rnd2, Rnd3, and
TC10 were expressed and purified from Escherichia coli by
nickel affinity chromatography, as we have described previ-
ously for Ras proteins (33). Expression and purification of
recombinant human FTase andGGTase-I from SF9 insect cells
(50% pure) were performed as we have described elsewhere
(33). FTase and GGTase-I activity were determined by meas-
uring the transfer of [3H]farnesyl or [3H]geranylgeranyl to the
Rho GTPase substrate in reaction mixtures containing (in 200
l) 50mMTrisHCl (pH 7.5), 1 mM dithiothreitol, 20mMKCl, 5
mM MgCl2. The concentration of recombinant FTase and
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GGTase-I was 0.5 M, whereas the GTPase protein substrate
concentrations were varied from 0 to 1.0 M. Reactions were
started by the addition of 20 ng of FTase or GGTase-I and
proceeded for 4 min at 37 °C.
Statistical Analysis—Data were analyzed by the use of Stu-
dent’s t test. In all analyses, p 0.05 was considered statistically
significant, and data are presented as mean  S.D.
RESULTS
Inhibition of Farnesyltransferase Blocks Rho Family GTPase
Localization and Function—Substrate specificity of FTase and
GGTase-I toward small GTPases is determined primarily by
the sequence of the CAAX tetrapeptide motif (Table 1). Bio-
chemical and structural studies of CAAX peptides in complex
with FTase and GGTase-I have defined rules that govern sub-
strate selectivity (34). Whereas the specific isoprenoid modifi-
cation of the classical Rho GTPases and of their highly related
isoforms (RhoA/B/C, Rac1/2/3, and Cdc42) has been con-
firmed in vivo, the precise isoprenoid modification of the
majority of Rho family GTPases has not been tested. Where
studied, the prenylation of Ras andRho small GTPases has been
found to be essential for proper subcellular localization. There-
fore, to determine the importance of farnesylation or gera-
nylgeranylation to Rho GTPase localization, we ectopically
expressed GFP-fusion Rho GTPase proteins to visualize their
subcellular localization in live cells and determined the ability
of treatment with the potent and highly selective FTI (FTI-
2153) and/orGGTI (GGTI-2417) to alter their subcellular loca-
tion (35). Exogenous expression of GFP fusion proteins has
been used extensively to evaluate the subcellular localization of
small GTPases and has been validated as an accurate reflection
of the subcellular location of the endogenous protein (24, 36,
37). For these analyses, we utilized wild-type (and therefore
predominantly GDP-bound) human Rho GTPases to avoid
potential complications in Rho GTPase localization due to
effector association or to altered interaction with RhoGDP dis-
sociation inhibitor proteins seen with the activated forms of
some Rho GTPases (24, 36, 37).
First, we verified the specificity and potency of the prenyl-
transferase inhibitors by determining their ability to disrupt the
membrane association and subcellular location of small
GTPases that are well known substrates of FTase and/or
GGTase-I (Fig. 1). Whether due to structural mutations or to
treatment with prenyltransferase inhibitors, nonprenylated
GFP-tagged small GTPases localize to the cytoplasm and
nucleus, similar to the distribution of GFP protein alone (Fig. 1)
(24, 35–39). H-Ras is normally localized to the plasma mem-
brane and has been shown previously to be solely farnesylated.
As expected, we found that treatment with FTI but not GGTI
caused mislocalization of GFP-H-Ras to the cytoplasm and
nucleus. RhoA is a substrate for GGTase-I but not FTase (40),
and, as seen previously, treatment with GGTI but not FTI
caused accumulation of GFP-tagged RhoA in the nucleus. In
contrast, RhoB has been found to exist in both farnesylated and
geranylgeranylated forms (41), and FTI treatment results in fur-
ther accumulation of the geranylgeranylated form (42). A pre-
vious study showed RhoB localization at the plasmamembrane
and endosomes (43), and our results confirm these observa-
tions. It has also been reported that FTI treatment of cells that
express RhoB caused loss of the plasma membrane-associated
pool, but not the endosome-associated pool, suggesting that
farnesylated RhoB is plasma membrane-associated, whereas
geranylgeranylated RhoB is endosome-associated (43). Surpris-
ingly, treatment of cells with either FTI or GGTI alone did not
cause a significant loss of either plasma membrane- or endo-
some-associated RhoB. Instead, a loss of RhoB frombothmem-
brane compartments, resulting in cytosolic and nuclear accu-
mulation, was observed only upon treatment with inhibitors of
both prenyltransferases. This result is consistent with the abil-
ity of RhoB to undergo alternative prenylation when either
FTase or GGTase-I activity is inhibited. However, our results
suggest that subcellular localization is not influenced by the
specific isoprenoid modification. Finally, K-Ras4B is normally
farnesylated but can be alternatively modified by GGTase-I in
vivo when cells are challenged with FTI (16, 17). Consistent
with these observations, we found that only concurrent treat-
ment with FTI and GGTI caused relocalization of K-Ras4B
from the plasma membrane to the cytoplasm and nucleus.
These results verify that treatment with FTI and GGTI can be
used to predict the species of isoprenyl group that is added to
Rho GTPases in vivo.
Unlike the classical Rho GTPases, Rnd3/RhoE and the
related Rnd1 and Rnd2 isoforms are predicted to be sub-
strates for FTase, and Rnd3 has been demonstrated to be
farnesylated in vivo (44). However, Rnd proteins contain car-
boxyl-terminal sequences similar to that seen in K-Ras4B,
terminating with a CXXM motif and possessing upstream
polybasic sequences like those that dictate the prenyltrans-
ferase interactions of K-Ras4B (45, 46). Consequently, it has
TABLE 1
Carboxyl-terminal membrane-targeting sequence elements of
human Ras and Rho GTPases
a Polybasic residues are in boldface type; putative or known palmitoylated (palm) cys-
teines are shaded gray; known or putative CAAX prenylation motifs are in boldface
type and underlined; underlined sequences comprise a GDP/GTP bindingmotif.
b Compiled from references cited in Ref. 67; RhoG andRhoH (68);Wrch-1 (23); Chp
(28). PM, plasma membrane; ER, endoplasmic reticulum; NE, nuclear envelope;
MT, mitochondria.
c The GTPase domains are followed by carboxyl-terminal tandem BTB domains.
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been speculated and assumed that Rnd proteins may also
undergo FTI-induced alternative prenylation (8).
To determine the prenylation specificity of Rnd proteins,
we first evaluated the ability of bacterially expressed proteins
to serve as substrates for FTase and GGTase-I in vitro. These
assays were done as we described previously (33), where each
GTPase was expressed in E. coli as amino-terminally His-
tagged proteins and purified to 90–95% purity (data not
shown). Insect cell-expressed purified recombinant FTase or
GGTase-I was incubated with increasing concentrations of
each Rnd protein and with saturation concentrations of
[3H]FPP or [3H]GGPP (0.5 M), respectively. For these anal-
yses, we included RhoB as a control, since previous studies
determined that RhoB is modified by both FTase-I and
GGTase-I in vitro and in vivo (41, 42). In agreement with
these previous observations, we
found that FTase and GGTase-I
catalyzed the farnesylation and
geranylgeranylation of RhoB,
respectively, in vitro (Fig. 2A).
As expected from the CAAX
sequence, all three Rnd proteins
were efficient substrates for FTase.
Consistent with the possibility that
Rnd proteins may undergo alterna-
tive prenylation in the absence of
FTase activity, we found that Rnd
proteins were capable of serving as
minor substrates for GGTase-I in
vitro, although with much lower
affinity than seen with FTase (Fig.
2A). This result is similar to our pre-
vious observations with K-Ras4B,
where we found that K-Ras4B, but
not H-Ras, was a substrate for
GGTase-I in vitro, albeit with a 140-
fold lower affinity than that for FTase
(33). Thus, like K-Ras4B, we antici-
pated that Rnd proteins are normally
farnesylated, but with FTI treatment,
Rnd proteins may become modified
by geranylgeranylation.
Consistent with published data,
we found that Rnd1 and Rnd3
showed plasma membrane associa-
tion, whereas Rnd2 lacked this asso-
ciation and was found in the cytosol
(Table 1). In addition, we observed
that Rnd1 and Rnd3, but not Rnd2,
caused cell rounding (47). Interest-
ingly, localization of all three Rnd
proteins was exquisitely sensitive to
treatment with FTI alone (Fig. 2B).
FTI and not GGTI treatment
resulted in the loss of plasma mem-
brane localization, accompanied by
increased cytoplasmic and nuclear
accumulation of all three Rnd pro-
teins. In vitro analysis of both K-Ras (33) and Rnd proteins (Fig.
2A) suggested that these proteins were strong substrates for
FTase but could also serve as weak GGTase substrates. How-
ever, unlike K-Ras, which undergoes alternative prenylation
and therefore displays unaltered subcellular localization when
treated with FTI, Rnd proteins were not found to be alterna-
tively prenylated in vivo to a detectable degree when cells were
treated with FTI (Fig. 2B).
In addition to disrupting subcellular localization, FTI treat-
ment reversed the cell rounding phenotype caused by ectopic
expression of Rnd1 and Rnd3. Although treatment with GGTI
had no effect on the subcellular localization of Rnd proteins,
interestingly, it induced an exaggerated rounding phenotype in
the majority of cells expressing ectopic Rnd1 (90%), probably
due to RhoA inactivation secondary to loss of RhoA gera-




























FIGURE 1. The specific isoprenoid modifications of Ras and Rho GTPases in vivo are accurately defined
using specific pharmacologic inhibitors of FTase and GGTase-I. NIH 3T3 cells were transiently transfected
with expression constructs for GFP alone or GFP-tagged fusion proteins of the indicated Ras or Rho GTPases
and treated with FTI-2153, GGTI-2417, or both (10 M each) or DMSO. Live cells were visualized using confocal
microscopy. Images shown are representative of three independent experiments with 80 cells examined per
assay. Scale bar, 10 m.
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nylgeranylation. Thus, unlike K-Ras4B, the weak GGTase-I
activity seen in vitromay not be physiologically significant, and
Rnd proteins do not appear to undergo significant, detectable
FTI treatment-induced alternative prenylation in vivo.
TC10 (CAAX 	 CLIT) and the closely related Rho GTPase,
TCL (CAAX 	 CSII) are predicted to be modified by farnesyl
and geranylgeranyl isoprenoids, respectively (34). In agreement
with this prediction, we found that recombinant TC10 was an
excellent substrate for FTase in vitro (Fig. 3A). However, TC10
can also serve as a weak substrate for GGTase-I, suggesting that
it may undergo FTI-induced alternative prenylation. To

































































































































































































































FIGURE 2. Rnd proteins are farnesylated in vitro and in vivo. A, in vitro RhoB is a strong substrate for both FTase and GGTase-I, whereas Rnd proteins
are strong substrates for FTase and weak substrates for GGTase-I. Purified recombinant RhoB and Rnd proteins were added to our standard FTase or
GGTase-I reaction mixture containing radiolabeled FPP or GGPP, respectively, and processed as described under “Experimental Procedures.” B, both
membrane association and function of Rnd proteins are inhibited by FTI treatment. NIH 3T3 cells were transiently transfected with expression constructs
for GFP-tagged fusion proteins with the indicated Rho GTPases and treated with FTI-2153, GGTI-2417, both (10 M each), or DMSO. Live cells were
visualized using confocal microscopy. Images shown are representative of three independent experiments with 80 cells examined per assay. Scale bar,
10 M.
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TC10 and evaluated sensitivity to FTI and GGTI treatment. In
agreement with previous findings (48), we found that ectopi-
cally expressed TC10 exhibited perinuclear endosomal local-
ization and induced formation of filopodia (Fig. 3B). We found
that treatment with FTI alone was sufficient to disrupt the
vesicular localization of TC10, resulting in a diffuse cytosolic
andnuclear accumulation, and additionally prevented filopodia
formation. GGTI treatment alone did not causemislocalization
of TC10 or block filopodia formation, and the combined treat-
ment with both inhibitors did not alter localization beyond
what was seen with FTI treatment alone. Ectopically expressed
TCL also exhibited perinuclear endosomal localization and
induced filopodia formation. Unexpectedly, although the
CAAX sequence suggested that this GTPase would be a
GGTase-I substrate (34), we found that FTI treatment alone
causedmislocalization andnuclear accumulation, although sig-
nificant vesicular staining and filopodia formation were
retained. The additional treatment with GGTI did not disrupt
this vesicular localization or filopodia formation, suggesting
that these activities may be prenylation-independent.
Like TC10, RhoD terminates in X 	 T, and therefore is pre-
dicted to be farnesylated (34). We found that RhoD endosome
association was reduced but not abolished by treatment with
FTI alone (Fig. 4). Althoughwe con-
sistently observed an increase in
nuclear accumulation of RhoD
upon treatment with FTI alone,
additional treatment with both
inhibitors did not disrupt the endo-
somal localization or impair filopo-
dia formation (Fig. 4). Thus, this
localization may be prenylation-in-
dependent. In summary, in contrast
to the classical Rho GTPases, we
determined that the localization of
six other RhoGTPases (Rnd1, Rnd2,
Rnd3, TC10, TCL, and RhoD) can
be disrupted with FTI treatment,
whereas GGTI treatment had little
to no effect on the localization of
these GTPases.
SomeRhoGTPases Are Substrates
for Both FTase and GGTase-I—
RhoH/TTF terminates in a CKIF
CAAX motif and, similar to TC21/
R-Ras2 (CVIF) (49), is therefore pre-
dicted to be modified by both farne-
syl and geranylgeranyl isoprenoid
groups (34). In agreement with this
prediction, we found that treatment
with either FTI or GGTI alone had
no effect on the perinuclear vesicu-
lar subcellular localization of RhoH
(Fig. 4). Instead, dual treatmentwith
FTI and GGTI resulted in complete
relocalization of RhoH to the cyto-
plasm and nucleus, indicating that
RhoH, like RhoB, may normally be
modified by both isoprenoids or that it is alternatively preny-
lated when challenged by FTI treatment. In addition to altered
subcellular localization of RhoH, we found that dual treatment
also resulted in a cell rounding phenotype in cells expressing
this Rho GTPase.
In agreement with previous observations (50), we found that
ectopically expressed wild-type Rif exhibited a plasma mem-
brane localization and induced filopodia formation (Fig. 4). Rif/
RhoF terminates in a CLLL motif and is predicted to be modi-
fied exclusively by GGTase-I. Consistent with this possibility,
we found that treatment with GGTI caused a complete and
striking nuclear accumulation of Rif. Unexpectedly, FTI treat-
ment alone caused a partial relocalization of Rif to the cyto-
plasm and nucleus (Fig. 4). Interestingly, the Rif-induced filop-
odia seen in untreated cells were not blocked by FTI treatment.
Although single treatment with either FTI or GGTI impaired
Rif localization, dual treatment had a synergistic effect on Rif
mislocalization, as judged by increased cytoplasmic andnuclear
fluorescence and lack of filopodia. These results indicate that
Rif is naturally prenylated by both FTase and GGTase-I and
exists in independent F- and GG-modified pools. Collectively,
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FIGURE 3. TC10 and TCL are farnesylated in vitro and in vivo. A, TC10 is a substrate for FTase and GGTase-I in
vitro. Assays were done as described in the legend to Fig. 2A and under “Experimental Procedures.” B, TC10
subcellular localization is partially dependent on farnesylation. NIH 3T3 cells transfected with expression con-
structs for GFP-tagged fusion proteins of human TC10 or TCL were treated with FTI-2153, GGTI-2417, both (10 M
each), or DMSO. Live cells were visualized using confocal microscopy. Images shown are representative of three
independent experiments with 80 cells examined per assay. Scale bar, 10 m.
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sess carboxyl-terminal CAAX motifs, nine can serve as sub-
strates for FTase.
The Membrane Association and/or Function of Rho GTPases
Is Dependent on Rce1- and Icmt-mediated Processing—Since
the majority of Rho GTPases (16 of 20) terminate in CAAX
motifs, they are also likely substrates for Rce1-catalyzed
removal of the -AAX residues and Icmt-mediated carboxyl
methylation of the prenylated cysteine. A recent study found
that the membrane association and biological function of far-
nesylated Ras proteins, but not of geranylgeranylated Rho
GTPases, were impaired in the absence of Rce1 or Icmt expres-
sion (22). However, other studies using pharmacologic inhibi-
tors suggested that geranylgeranylated protein function also
depends on thesemodifications (51, 52). Therefore, to elucidate
whether the specific isoprenoid modification of a Rho GTPase
dictates a dependence on Rce1-catalyzed -AAX cleavage and
Icmt-mediated carboxyl methylation, we evaluated the subcel-
lular localization of Rho GTPases in MEF cell lines deficient in
Rce1 (Rce1/) or Icmt (Icmt/).
For these analyses, we transiently transfected wild-type,
Rce1/, and Icmt/ MEFs with expression constructs for
K-Ras4B or RhoGTPases as GFP fusion proteins. Plasmamem-
brane localization of K-Ras4B has been demonstrated to be par-
tially dependent on Rce1- and Icmt-mediated carboxyl-termi-
nalmodifications (22, 53). In agreement with earlier studies, we
found that GFP-K-Ras4B was partially localized to the cyto-
plasm in both Rce1/ and Icmt/ cells (Fig. 5A). However,
this shift was subtle, and significant associationwith the plasma
membrane was retained in each deficient cell line. Although
RhoA localization was unchanged
in Rce1/ MEFs, we unexpectedly
found that RhoA localization, shown
previously tobe independentofRce1-
and Icmt-mediated modifications
(22), displayed increased nuclear and
cytosolic accumulation in Icmt/
cells (Fig. 5A). The differential sensi-
tivity to loss of Rce1 compared with
Icmt is surprising, since proteolytic
cleavage of the AAX residues to
expose the prenylated cysteine to
Icmt is thought to be required for
methylation to occur.
Although RhoA and RhoB share
significant sequence (83%) and bio-
chemical identity, RhoB can be
modified by both farnesylation and
geranylgeranylation, probably in
distinct pools. In contrast to RhoA,
we found that the absence of Rce1
expression resulted in decreased
RhoB plasma membrane localiza-
tion and increased cytoplasmic and
nuclear accumulation in Rce1/
MEFs, whereas normal localization
was maintained in Icmt/ MEFs
(Fig. 5A). Our observations contrast
with previous analyses that found
that RhoB localization was not dependent on either Rce1 or
Icmt expression (22).
Based on previous observations of farnesylated and gera-
nylgeranylated Ras proteins, the subcellular localization of far-
nesylated Rho GTPases was expected to be dependent on Rce1
and Icmt activity (22). Surprisingly, the farnesylated RhoD and
RhoH GTPases displayed subtle changes in their subcellular
distribution in the null MEFs. Expression of RhoD in Rce1/
and Icmt/ MEFs resulted in reduced association with the
plasma membrane, whereas vesicular localization was
unchanged (Fig. 5A). Although loss of Rce1 function did not
impair RhoH plasma membrane association, it did result in
reduced RhoH association with endomembranes (Fig. 5A). In
Icmt/ cells, RhoH displayed a loss of endomembrane associ-
ation and was found on vesicles throughout the cytoplasm.
We found that even closely related isoforms differed substan-
tially in their degree andmannerof dependenceonRce1 and Icmt.
When expressed in Rce1/ cells, Rnd1 consistently demon-
strated a weak increase in nuclear staining yet retained significant
plasmamembrane association. Rnd2, which is normally cytoplas-
mic, showed increased endomembrane localization as well as
increased negative imaging of internal organelles in Rce1/ cells
(Fig. 5A). Finally, Rnd3 expression in Rce1/ cells showed a sig-
nificant decrease in plasma membrane association, accompanied
by substantial cytosolic distribution and some nuclear accumula-
tion (Fig. 5A). Therefore, we concluded that all three Rnd proteins
require Rce1-mediated AAX proteolysis for proper localization
but to very different degrees, with Rnd3 being the most sensitive.
Interestingly, Rnd1 and Rnd2 displayed far greater sensitivity to
FIGURE 4. Atypical Rho GTPases are not simple substrates for FTase or GGTase-I. RhoH and Rif are farne-
sylated and/or geranylgeranylated in vivo. NIH 3T3 cells were transfected with expression constructs for the
indicated GFP-tagged Rho GTPase and treated with FTI-2153, GGTI-2417, or both (10 M each) or DMSO. Live
cells were visualized using confocal microscopy. Images shown are representative of three independent exper-
iments with 80 cells examined per assay. Scale bar, 10 m.
Rho GTPase Posttranslational Processing and Subcellular Association
SEPTEMBER 12, 2008 • VOLUME 283 • NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 25157
the absence of Icmt-mediated methylation than to the absence of
Rce1-mediatedproteolysis,withbothproteins showing significant
diffuse cytosolic staining and extensive nuclear accumulation.
Rnd3 also exhibited a complete loss of plasma membrane and
endomembrane localization that was
accompanied by increased cytosolic
but not nuclear distribution (Fig. 5A).
Finally, consistent with the lack of
Rnd1 plasma membrane association
seen upon loss of Icmt but not upon
loss of Rce1 activity, Rnd1-induced
rounding was abrogated completely
in Icmt-deficient but not at all in
Rce1-deficient cells.
Proper subcellular localization of




carboxyl methylation (Fig. 5A).
Both of these farnesylated GTPases
displayed reduced plasma mem-
brane associationwhilemaintaining
their vesicular localization in
Rce1/ cells. In contrast, in the
absence of Icmt, TCL was strongly
mislocalized to the cytosol and
nucleus, whereas TC10 protein
localization demonstrated only a
mild loss of membrane association
with no nuclear accumulation.
Thus, the loss of carboxymethyla-
tion is more critical for membrane
association of TCL than of TC10.
Last, despite the loss of Rif-in-
duced filopodia in Rce1-deficient
cells, we found that Rif maintained
its plasma membrane localization
(Fig. 5B). Expression of Rif in
Icmt/ cells did not cause mislo-
calization of Rif as determined by
increased cytoplasmic or nuclear
localization. However, the absence
of Icmt resulted in an altered
appearance and spatial redistribu-
tion of Rif-induced filopodia from the cell periphery to the dor-
sal side of the cell (Fig. 5B).
Complexity of Predicting Palmitoylation of Carboxyl-termi-
nal Cysteines—In addition to CAAX processing, a second car-
boxyl-terminal sequence motif is required for proper subcellu-
lar localization and membrane association. Ras (H-Ras and
N-Ras) and Rho (RhoB and TC10) GTPases with cysteine resi-
dues upstream of the CAAX motif undergo posttranslational
modification by palmitate that is critical for their proper sub-
cellular localization (24, 54). The three Rac isoforms (Rac1, -2,
and -3) contain an invariant cysteine residue at position 178 in
the hypervariable domain, several residues amino-terminal to
the cysteine of the CAAX motif (Table 1). Furthermore, this
cysteine residue and its flanking sequences are conserved in
evolution and are found in Rac1 orthologs in Drosophila,
Danio, and Xenopus (Table 2). Since there are no known con-
sensus palmitoylation motifs that can predict whether a given
A.
B.
FIGURE 5. Differential requirements for Rce1- and Icmt-mediated postprenyl processing in the subcel-
lular localization and function of Rho family proteins. Wild-type, Rce1/, and Icmt/ MEFs were tran-
siently transfected with expression constructs for GFP-tagged fusion proteins of the indicated Rho GTPases. A,
live cells were visualized using confocal microscopy. Images shown are representative of three independent
experiments with 80 cells examined per assay. B, Icmt-mediated processing of Rif is not required for membrane
association but contributes to subcellular membrane distribution. GFP-Rif localization was examined by Z-section-
ing. The bottom and top stacks of each cell were examined for the presence of filopodia, and images shown are
representative of three independent experiments with 50 cells examined per assay. Scale bar, 10 m.
TABLE 2
Evolutionary conservation of the Rac1 carboxyl-terminal cysteine
a Conserved cysteine residue is shaded; CAAXmotif is in boldface type and in italics.
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cysteine residue is a substrate for palmitoylation (55), experi-
mental analyses are required to establish definitively whether
these sites within Rac1, Rac2, Rac3,
and TCL are palmitoylated. There-
fore, we determined whether these
proteins were palmitoylated in vivo.
To evaluate the palmitoylation
status of the Rac proteins, we used
biotin-BMCC labeling to analyze
protein palmitoylation. This assay
involves hydrolyzing the thioester
bond that links fatty acid groups to
cysteines and treating with a biotin-
ylated compound that recognizes
and binds to the free sulfhydryl
group generated upon cleavage of
the thioester bond (31).We recently
applied this assay to determine that
the Chp and Wrch-1 Rho GTPases
are palmitoylated (23, 28). Using
this technique, we found efficient
labeling of TC10 (Fig. 6A), which is
consistentwith the previous sugges-
tion that TC10 undergoes palmitoy-
lation (24). Surprisingly, none of the
Rac proteins was labeled, indicating
that Rac isoforms are not palmitoy-
lated (Fig. 6A). Nevertheless,
although the Rac C178 does not
appear to undergo palmitoylation,
the strong conservation of this cys-
teine in Rac orthologs and paralogs
through evolution supported an
important functional role for this
residue. To address this possibility,
we generated missense mutants
containing a Cys178 to Ser substitu-
tion for all three Rac isoforms. Sur-
prisingly, this substitution did not
affect subcellular localization or
impair lamellipodia formation of
activated Rac1, Rac2, or Rac3 when
these proteins were expressed in
NIH 3T3 cells (Fig. 6B). However,
this substitution did lead to a mod-
est but reproducible reduction in
Rac1(61L)-induced soft agar colony
formation (Fig. 6C), suggesting that
this conserved cysteine is of func-
tional importance despite not being
a site of palmitoylation. We noted a
similar limited reduction in the
transforming activity of activated
Rac2 and Rac3 (data not shown).
TCL also possesses two carboxyl-
terminal putative palmitoylation
sites similar to TC10 that may serve
as additional signals to control
proper subcellular localization. More specifically, TCL pos-
sesses a cysteine residue immediately adjacent to the CAAX
FIGURE 6. Distinct roles of conserved cysteines in palmitoylation and protein function of Rac. A, 293T cells
were transiently transfected with expression constructs for GFP-tagged activated Rac1(61L), Rac2(12V), and
Rac3(61L) with or without an additional C178S mutation; TC10; or empty vector and subjected to the biotin-
BMCC labeling assay. Levels of biotin-labeled GTPases were measured by Western blotting with streptavidin-
horseradish peroxidase (top). Expression of GFP-tagged constructs was confirmed by immunoblotting with
anti-GFP antibodies (bottom). B, NIH 3T3 cells were transiently transfected with expression vectors encoding
GFP-tagged activated Rac1(61L) or mutant Rac1(61L/178S) proteins and stained with Alexa 594-conjugated
phalloidin to visualize the actin cytoskeleton. Images shown are representative of three independent experi-
ments with 80 cells examined per assay. C, mutation of C178 causes a limited reduction in Rac transforming
activity. Single cell suspensions of NIH 3T3 cells stably expressing activated Rac1 proteins were suspended in
soft agar, and colony formation was monitored after 2 weeks. The number of colonies was quantified as
described under “Experimental Procedures.” Colony numbers were normalized to those seen with Rac1(61L).
D, expression of hemagglutinin (HA)-tagged Rac constructs was confirmed by immunoblotting with anti-
hemagglutinin antibodies. IP, immunoprecipitation; WB, Western blot.
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motif, a topology found in the palmitoylated TC10 and
RhoB, suggesting that it may undergo palmitoylation. How-
ever, similar to Rac, we found that TCL did not exhibit sig-
nificant biotin-BMCC labeling (Fig. 7A). These results high-
light the complex and highly unpredictable nature of
sequences that dictate carboxyl-terminal palmitoylation of
prenylated proteins.
Our results suggest that TC10, but not TCL, can be palmit-
oylated. Therefore, we speculated that the increasedmembrane
affinity of TC10 due to palmitoylation may account for its
insensitivity to the loss of Icmt-mediated processing that we
described above (Fig. 5). To address this possibility, we treated
cells expressing TC10 and TCL with 2-BP, a well characterized
inhibitor of palmitoylation in vivo (24, 28–30), and determined
subcellular localization of TC10 and TCL. As anticipated from
the lack of biotin-BMCC labeling, treatment with 2-BP had no
effect on the subcellular localization of TCL in wild-type or
Icmt/ MEFs (Fig. 7B). Unexpect-
edly, and in contrast to a previous
study using COS-1 cells (24), we
found that plasma membrane asso-
ciation of TC10 was insensitive to
2-BP treatment in wild-type MEFs,
suggesting that loss of palmitoyla-
tion is not sufficient to mislocalize
TC10 (Fig. 7B). However, we did
find that plasma membrane associ-
ation of GFP-TC10 was lost in
Icmt/ MEFs treated with 2-BP,
leading to an increase in cytosolic
accumulation (Fig. 7B). These
results suggest that carboxyl methy-
lation and palmitoylation modifica-
tions are partially redundant and
cooperate to target TC10 to the
plasma membrane. Furthermore,
only prior farnesylation and not full CAAX-mediated process-
ing, including carboxyl methylation, is a necessary prerequisite
for palmitoylation.
DISCUSSION
Due to the critical role of Rho family small GTPases in onco-
genesis and their dependence on CAAX processing for proper
localization and function, pharmacological inhibitors of the
CAAX-processing enzymes FTase, GGTase-I, Rce1, and Icmt
are considered promising approaches to block Rho small
GTPase function for cancer treatment (9). In the current study,
we utilized pharmacologic and genetic approaches to deter-
mine the sequence requirements and roles of CAAX-signaled
modifications in dictating the subcellular location and function
of atypical members of the Rho GTPase family. Our results
demonstrate the complexity of sequence requirements that
direct prenyltransferase specificity and uncover functional
roles for protein prenylation and postprenyl processing in Rho
GTPase biology. Additionally, we have shown that the localiza-
tion (and presumably the activity) of a majority of human Rho
family GTPases may be blocked effectively by pharmacologic
inhibitors of FTase, Rce1, and/or Icmt (Table 3). Finally, we
found that the carboxyl-terminal sequences that signal palmi-
toylation of Rho GTPases are complex and not defined simply
by the presence of a cysteine residue.
Our analyses of the specificity of CAAX-directed prenylation
uncovered unexpected results, in light of the previously pub-
lished rules governing substrate selectivity derived from in vitro
prenylation assays (56, 57) and from recent crystallographic
analyses of FTase and GGTase-I in complex with validated
CAAX-containing prenyltransferase substrate peptides (34).
These prior studies determined that the X residue of the
CA1A2Xmotif is the primary determinant of prenyltransferase
specificity, such that FTase favors motifs where X is a hydro-
phobic (Met), polar (Gln), or small (Cys, Ser, Thr, or Ala) resi-
due. In contrast, GGTase-I favorsmotifs whereX is Leu but can
also accommodate Met, Phe, Ile, and Val. The nature of the A1
and A2 residues alone does not dictate enzyme selectivity. In
contrast to the classical Rho family members that are known to
FIGURE 7. Methylation and palmitoylation act as redundant membrane targeting signals for TC10 local-
ization. A, 293T cells were transiently transfected with expression constructs for GFP-tagged TC10, TCL, or
empty vector and subjected to the biotin-BMCC labeling assay. Levels of biotin-labeled GTPases were meas-
ured by Western blotting with streptavidin-horseradish peroxidase (top). Expression of GFP-tagged constructs
was confirmed by immunoblotting with anti-GFP antibodies (bottom). B, wild-type or Icmt/ MEFs were
transiently transfected with expression constructs for the indicated GFP-tagged Rho GTPase. Cells expressing
GFP-TCL and GFP-TC10 were treated with 100 M 2-BP and imaged alive. Images shown are representative of
three independent experiments with 80 cells examined per assay. Scale bar, 10 m. IP, immunoprecipitation;
WB, Western blot.
TABLE 3
Contribution of prenyltransferase, Rce1, and Icmt activities to
subcellular membrane association and localization
Name
Sensitivitya Dependencea
FTI GGTI FTI  GGTI Rce1 Icmt
K-Ras4B     
RhoA     
RhoB     
RhoC   NDb ND ND
Rac1     
Rac2    ND ND
Rac3    ND ND
RhoG ND ND ND ND ND
Rnd1     
Rnd2     
Rnd3     
Cdc42    ND ND
TC10     
TCL     
RhoD     
Rif     
RhoH     
Wrch-1c    ND ND
Chpc    ND ND
a Altered subcellular localization and/or loss of morphologic alterations: , no
effect; , limited effect; , strong effect.
b ND, not determined.
c Compiled from our previous analyses (23, 28).
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be prenylated by GGTase-I, these rules predict that some Rho
family members are farnesylated in vivo. In general agreement
with these predictions, we found that a majority of the nonca-
nonical Rho GTPases are substrates for FTase in vivo: Rnd1–3,
TC10, TCL, RhoD, and Rif (Table 3). However, our results also
suggest that these rules are imperfect. Thus, although previous
analyses with peptide substrates indicated that CAAX motifs
whereX is Ile can be recognized efficiently byGGTase-I in vitro
(56, 58), we found that at least some proteins terminating in
such a motif (e.g. TCL) are still more effective substrates for
FTase in vivo. Finally, two Rho GTPases exhibited complex
responses to prenyltransferase inhibition. Rif terminates in the
same CAAX motif as Rac1 (CLLL), and, as expected, GGTI
treatment caused complete mislocalization and nuclear accu-
mulation of this GTPase and a block of Rif-induced filopodia
formation. However, FTI treatment caused only partial disrup-
tion of Rif subcellular localization, increasing nuclear accumu-
lation, although filopodia induction was not blocked. Perhaps,
like RhoB (CKVL), a subset of Rif is farnesylated, or alterna-
tively, Rif subcellular localization is dependent on another far-
nesylated protein. Finally, whereas RhoD subcellular localiza-
tion was disrupted partially with FTI treatment, surprisingly,
the combined treatment with FTI and GGTI did not cause fur-
ther disruption. One logical interpretation of these data is that
RhoD subcellular localization is not dependent exclusively on
prenylation and may instead be regulated by palmitoylation, as
found for other endosomal GTPases,Wrch-1 and Chp (23, 28).
In addition to defining the preferred prenyl modification of
the Rho family members, we were also interested in determin-
ing whether these proteins would be alternatively prenylated
when challenged with prenyltransferase inhibitors. Of the nine
Rho family members evaluated, only RhoH showed the poten-
tial to be alternatively prenylated. This result is in agreement
with the prediction that CAAX motifs where X is Phe are sub-
strates for both FTase andGGTase-I (34). Surprisingly, the Rnd
proteins, which have been speculated to undergo FTI-induced
alternative prenylation (8), were exquisitely sensitive to FTI
treatment alone and did not undergo detectable FTI-induced
alternative prenylation by GGTase-I. This result was unex-
pected, because the carboxyl-terminal sequences of Rnd pro-
teins are similar to that of K-Ras4B, which does undergo FTI-
induced alternative prenylation. Together, these data suggest
that alternative prenylation of Rho proteins is a rare event and
that most Rho targets of FTase inhibitors will probably be sen-
sitive to inhibition of FTase alone. Finally, we recently deter-
mined that Rnd3 expression is up-regulated in humanmelano-
mas (59), and a recent study suggested that Rnd3 promotes
melanoma invasion (60). Perhaps Rnd3 may represent an
important target for the anti-tumor activity seen with FTIs in
melanomas and other cancers that overexpress Rnd3.
Efforts to develop inhibitors for the postprenyl processing
steps regulated by Rce1 and Icmt have intensified since
K-Ras4B was determined to be alternatively prenylated when
treated with FTI (9). The possibility that pharmacologic inhib-
itors of these two enzymes may exhibit anti-Ras activity is sup-
ported by recent genetic studies using Rce1- or Icmt-deficient
MEFs (53). These studies showed that K-Ras and H-Ras-medi-
ated transformation is indeed impaired by a deficiency in either
enzyme. However, in light of the significant number of CAAX-
terminating proteins encoded in the human genome, including
many proteins with established roles in normal cell prolifera-
tion and survival, there is significant concern that such inhibi-
tors will be intolerable to patients due to normal cell toxicity.
The observation that transformation caused by the B-Raf onco-
protein, which is not a substrate for Icmt, was also dependent
on Icmt activity supports this concern (61). This result sug-
gested that the perceived Icmt deficiency-induced inhibition of
K-Ras activity is not due simply to impaired K-Ras function;
indeed, the authors provided evidence that the phenotype may
instead be due to impaired RhoA function.
A recent study of RhoA, as well as of Rac1 and Cdc42, sug-
gested that these final two postprenyl modifications are not
required for geranylgeranylated proteins (22). However, in gen-
eral, we found that the function of most Rho family members,
including geranygeranyl-modified GTPases, were dependent
on both Rce1 and Icmt function for proper subcellular localiza-
tion and/or function. In contrast to this previous report, we
observed that the subcellular localization of RhoAwas sensitive
to loss of Icmt expression. In the previous study, an activated
RhoA(63L) construct was used to evaluate the dependence of
Icmt function on RhoA localization, whereas in the current
study, we used wild-type RhoA. Therefore, to determine
whether wild-type and activated RhoA are differentially
dependent on Icmt, we also evaluated the localization of acti-
vated RhoA in Icmt/ MEFs and found that, unlike wild-type
RhoA, it was unaffected by Icmt deficiency (data not shown).
This differential dependence may reflect a role for carboxyl
methylation in the interaction of Rho proteins with Rho GDP
dissociation inhibitors, an interaction that is sensitive to the
GTP-bound state of the protein. Regardless of the mechanism
behind the differential requirements for Icmt activity for wild-
type versusmutant RhoA, we conclude that RhoA represents a
functionally important anti-cancer target of Icmt inhibitors,
since there are no known RhoA-activating mutations that nat-
urally occur in cancer. In support of this conclusion, loss of Icmt
has been shown to decrease the stability of RhoAproteinwithin
the cell (61, 62). In addition, inhibition of carboxyl methylation
has been shown to increase permeability of the endothelial cell
monolayer as well as to increase endothelial cell apoptosis
through a RhoA-dependent mechanism (51). Thus, we con-
clude that the specific isoprenoid modification of a CAAX
motif-containing protein will not be a reliable determinant of
the requirement for Rce1 and Icmt activity. Furthermore, our
results suggest that Icmt and Rce1 remain attractive targets for
the development of anti-cancer therapeutics.
In addition to RhoA, we also found that RhoB was highly
sensitive to loss of Rce1 and somewhat sensitive to loss of Icmt
function. This result also differed from those of Philips and co-
workers (22), who concluded that RhoB functionwas not depend-
ent on the activity of either enzyme. Since both of these studies
used enzyme-deficientMEFs, the basis for the difference in results
is not clear.Onepossibility is subtle differences in cell culture con-
ditions that alter theactivityof other enzymesor interactingchap-
erone proteins, but this remains to be determined.
Rce1-mediated proteolysis is a prerequisite processing step
essential for Icmt-mediated carboxyl methylation. As such, it
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might be expected that loss of Rce1 function would have more
drastic consequences than loss of Icmt. However, whereas
Rce1-deficient mice died during late gestation or soon after
birth, Icmt-deficient mice showed a more severe phenotype,
with virtually all of the knock-out embryos (Icmt/) dying by
midgestation (25). This greater severity had been explained by
the fact that there are additional Icmt substrates that are not
Rce1 substrates and that it is the mislocalization of these addi-
tional proteins that results in the more severe phenotypic
changes. In addition, conditional deletion of Icmt in mouse
fibroblasts has been shown to cause a more dramatic reduction
in Ras-induced transformation when compared with condi-
tional deletion of Rce1. Interestingly, we found thatmany of the
evaluated Rho family members were differentially sensitive to
loss of Rce1 and Icmt. Asmentioned previously, RhoB appeared
to be more sensitive to loss of Rce1, whereas RhoA was more
dependent on Icmt. In addition, we found that the Rnd proteins
were sensitive to loss of both processing steps, although the loss
of Icmt was much more dramatic. Finally, loss of Rce1 blocked
Rif-induced filopodia but did not impair localization, whereas
conversely loss of Icmt altered the spatial orientation of Rif
without blocking filopodia formation. One explanation for the
differential consequences of the loss of Rce1 and Icmt is that
Rho GTPases may be less affected by the presence of the -AAX
extension than they are by the presence of the carboxylate
anion (63). In accordance with this hypothesis, protein stability
as measured by cellular half-life is significantly altered by both
pharmacologic and genetic disruption of Icmt (61, 62). The
mechanism of these changes in protein stability is unknown,
although it could be the result of altered recognition by degra-
dative enzymes.
Our studies found unexpectedly that the Rac isoforms, as
well as TCL, do not undergo palmitoylation. Although an
important role for palmitoylated cysteines in facilitating the
proper subcellular localization and membrane association of
Ras and Rho GTPases is well established, the substrate speci-
ficity and enzymology of protein palmitoylation remain
poorly understood (64). Aside from a conserved cysteine res-
idue, a defined consensus sequence that directs protein
palmitoylation has not been elucidated. Mutagenesis studies
suggest that there will not be a strict requirement for these
flanking sequences. Thus, although the conserved cysteine
residue found in Rac small GTPases seemed ideally suited to
be a substrate for palmitate addition, our results showed
clearly that these cysteines were not palmitoylated and again
highlight the difficulty of predicting palmitoylation simply
by examining amino acid sequence. Future studies with spe-
cific protein acyltransferases (24 human members) will be
required to determine if rules can be established for predict-
ing substrates for palmitoylation.
In summary, our analyses of the Rho GTPase family reveal
that the function of a majority of Rho GTPases will be sensitive
to FTI treatment as well as to inhibitors of Rce1 and Icmt. Our
observations also reveal the complex and varied roles for
CAAX-mediated posttranslational modifications for the func-
tion of Rho family GTPases. FTIs are currently in phase II/III
clinical trials, and our studies identify additional targets that
may contribute to their anti-tumor activities. Recent preclinical
studies in mouse models suggest that GGTIs will also exhibit
anti-tumor activities (10, 65, 66), and our studies identify those
Rho GTPases that may also be important targets for these
inhibitors (10). Finally, although the development of pharma-
cologic inhibitors of Rce1 or Icmt has been limited to date (9),
our findings provide further validation for these two enzymes as
potentially important drug targets and support a therapeutic
value for such inhibitors.
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